These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 22125070)

  • 21. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW; Ren R
    Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants.
    Skaggs BJ; Gorre ME; Ryvkin A; Burgess MR; Xie Y; Han Y; Komisopoulou E; Brown LM; Loo JA; Landaw EM; Sawyers CL; Graeber TG
    Proc Natl Acad Sci U S A; 2006 Dec; 103(51):19466-71. PubMed ID: 17164333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of allosteric kinase inhibitors by displacement of active site probes.
    Lebakken CS; Reichling LJ; Ellefson JM; Riddle SM
    J Biomol Screen; 2012 Jul; 17(6):813-21. PubMed ID: 22453235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Working at the cutting edge: the creation of allosteric ribozymes.
    Warashina M; Kuwabara T; Taira K
    Structure; 2000 Nov; 8(11):R207-12. PubMed ID: 11080644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergy and Antagonism between Allosteric and Active-Site Inhibitors of Abl Tyrosine Kinase.
    Johnson TK; Bochar DA; Vandecan NM; Furtado J; Agius MP; Phadke S; Soellner MB
    Angew Chem Int Ed Engl; 2021 Sep; 60(37):20196-20199. PubMed ID: 34292655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions.
    Bertilaccio MT; Scielzo C; Simonetti G; Ten Hacken E; Apollonio B; Ghia P; Caligaris-Cappio F
    Leukemia; 2013 Mar; 27(3):534-40. PubMed ID: 23041721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rational drug repurposing using sscMap analysis in a HOX-TALE model of leukemia.
    Kettyle LM; Liberante FG; Thompson A
    Methods Mol Biol; 2014; 1196():349-70. PubMed ID: 25151174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Switch Pocket Kinase: An Emerging Therapeutic Target for the Design of Anticancer Agents.
    Kaur C; Sharma B; Nepali K
    Anticancer Agents Med Chem; 2022 Aug; 22(15):2662-2670. PubMed ID: 35379129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Preclinical models in oncology].
    Vrignaud P
    Bull Cancer; 2011 Nov; 98(11):1355-61. PubMed ID: 22023796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mouse models for pre-clinical drug testing in leukemia.
    Bhatia S; Daschkey S; Lang F; Borkhardt A; Hauer J
    Expert Opin Drug Discov; 2016 Nov; 11(11):1081-1091. PubMed ID: 27562952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Xenograft models for the preclinical evaluation of new therapies in acute leukemia.
    Lee EM; Bachmann PS; Lock RB
    Leuk Lymphoma; 2007 Apr; 48(4):659-68. PubMed ID: 17454623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting TOR dependence in cancer.
    Janes MR; Fruman DA
    Oncotarget; 2010 May; 1(1):69-76. PubMed ID: 20657741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies.
    Tasian SK; Teachey DT; Rheingold SR
    Front Oncol; 2014; 4():108. PubMed ID: 24904824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular therapeutic approaches for pediatric acute myeloid leukemia.
    Tasian SK; Pollard JA; Aplenc R
    Front Oncol; 2014; 4():55. PubMed ID: 24672775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia.
    Janes MR; Vu C; Mallya S; Shieh MP; Limon JJ; Li LS; Jessen KA; Martin MB; Ren P; Lilly MB; Sender LS; Liu Y; Rommel C; Fruman DA
    Leukemia; 2013 Mar; 27(3):586-94. PubMed ID: 23090679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The in vivo evaluation of active-site TOR inhibitors in models of BCR-ABL+ leukemia.
    Janes MR; Fruman DA
    Methods Mol Biol; 2012; 821():251-65. PubMed ID: 22125070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of the potent dual Abl/Src tyrosine kinase inhibitor FB2 against Bcr-Abl positive cell lines in vitro and in vivo.
    Yuan X; Zhang Y; Zhang H; Jin J; Li X; Liu H; Feng Z; Chen X
    Leuk Res; 2011 Feb; 35(2):237-42. PubMed ID: 20739063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl.
    Xu F; Shi X; Li S; Cui J; Lu Z; Jin Y; Lin Y; Pang J; Pan J
    Bioorg Med Chem; 2010 Mar; 18(5):1806-15. PubMed ID: 20149665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Target of rapamycin signaling in leukemia and lymphoma.
    Vu C; Fruman DA
    Clin Cancer Res; 2010 Nov; 16(22):5374-80. PubMed ID: 20826559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.